Preview

Rational Pharmacotherapy in Cardiology

Advanced search

CHOICE OF LISINOPRIL FOR TREATMENT OF HYPERTENSION IN PATIENTS WITH CONCOMITANT DISEASES

https://doi.org/10.20996/1819-6446-2014-10-5-565-571

Full Text:

Abstract

Rationale and benefits of the use of the ACE inhibitor lisinopril in the clinical practice as an antihypertensive drug are considered. Special attention is paid to the organ protective effects of lisinopril and its application in some clinical situations (combination of hypertension with chronic obstructive pulmonary disease, elderly patients, and concomitant liver diseases).

About the Author

N. A. Dzhaiani
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
Delegatskaya ul. 20/1, Moscow, 127473 Russia


References

1. Shalnova S., Kukushkin S., Manoshkina E., Timofeev T. Hypertension and adherence to therapy. Vrach 2009; 12: 39-42. Russian (Шальнова С., Кукушкин С., Маношкина Е., Тимофеева Т. Артериальная гипертензия и приверженность терапии. Врач 2009;12: 39-42).

2. National guidelines for the diagnosis and treatment of hypertension (4th revision) . Sistemnie Gypertensii 2010 (3): 5-26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертензии (четвертый пересмотр). Системные гипертензии 2010; (3): 5-26).

3. 2013 ESH/ESC Guidelines for themanagement of arterial hypertension. The Task Force for the management ofarterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013; 31(7):1281-357.

4. The Heart Outcomes Prevention Evaluation study Investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 14Б-1БЗ.

5. Preobragenskii DV, Sidorenko BA, Botyraliev TA. ACE inhibitors and AT1 blockers in clinical practice. Moscow: Alliance-Presid; 2002. Russian (Преображенский Д.В., Сидоренко Б.А., Ботыралиев Т.А. Ингибиторы АПФ и АТ1-блокаторы в клинической практике. М.: Альянс-ПРЕСИД; 2002).

6. Komissarenko IA, Lazebnik LB, Mikheeva OM. Features metabolism of antihypertensive drugs in patients with pathology of the digestive system. Kardiovaskulyarnaya Terapiya i Profilaktika 2009; 8 (6) suppl 1: 239. Russian (Комиссаренко И.А., Лазебник Л. Б., Михеева О.М. Особенности метаболизма гипотензивных препаратов у больных с патологией органов пищеварения. Кардиоваскулярная Терапия и Профилактика 2009; 8 (6) Приложение 1: 239).

7. Komissarenko IA, Mikheeva M. Drozdov VN, et al. Use of inhibitors of angiotensin-converting enzyme inhibitors in hypertensive patients on a background of liver disease. Consilium medicum 2007; 9 (11): 72-5. Russian (Комиссаренко И. А., Михеева О. М., Дроздов В. Н., и др. Применение ингибиторов ангиотензин-превращающего фермента у больных артериальной гипертонией на фоне патологии печени. Consilium medicum 2007; 9(11): 72-5).

8. Dahlof B., Lindholm L.H., Hansson L., et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338: 1281-5.

9. Packer M., Pool-Wilson P.A., Armstrong P.W. et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitors, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-8.

10. Gruppo Italiano per lo Studio della Sopravvivenzanell' infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryltrinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.

11. Chaturvedi N, Stevenson J, Fuller JH et al. Randomised placebo controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997; 349: 1787-92.

12. Evdokimova AG, Evdokimov VV, Smetanin AV, Junco SA. Hypertension and high risk of cardiovascular disease: focus on lisinopril. Trudnyy Patsient 2010; 11: 4-9. Russian (Евдокимова А.Г., Евдокимов В.В., Сметанин А.В., Юнко С.А.. Артериальная гипертензия и высокий риск сердечно-сосудистых осложнений: фокус на лизиноприл. Трудный Пациент 2010; 11: 4-9).

13. Diamant M., Vincent H.H. Lisinopril versus enalapril: evaluation of trough: peakratioby ambulatory blood pressure monitoring. J Hum Hypertens 1999;13(6):405-12.

14. Landmark K., Tellnes G., Fagerthun H.E., Larsen S. Treatment of hypertension with the ACE inhibitor lisinopril. A multicenter study of patients with mild to moderatehypertension in general practice (in Norwegian). Tidsskr Nor Laegeforen 1991;111(26):3176-9.

15. Motero Carrasco J. A comparative study of the efficacy of lisinopril versus quinapril in controlling light to moderate arterial hypertension. A follow-up with ABPM (in Spanish). Rev Esp Cardiol 1995;48(11):746-53.

16. Reisin E., Weir M.R., Falkner B. et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997; 30(1 Pt. 1): 140-5.

17. Rosei E.A., Rizzoni D., Comini S. et al. Evaluation of the efficacy and tolerability ofnebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized,multicentre, double-blind study. Blood Press Suppl 2003;1:30-5.

18. Jensen H.A. Efficacy and tolerability of lisinopril compared with extended release felodipine in patients with essential hypertension. Danish Cooperative Study Group. Clin Exp Hypertens A 1992;14(6): 1095-110.

19. Os I., Bratland B., Dahlцf B. et al. Lisinopril or nifedipine in essential hypertension? A Norwegian multicenter study on efficacy, tolerability and quality of life in 828patients. J Hypertens Suppl 1991;9(6):S382-3.

20. Stergiou G.S., Efstathiou S.P., Roussias L.G., Mountokalakis T.D. Blood pressure and pulse pressurelowering effects, trough: peak ratio and smoothness index of telmisartan compared with lisinopril. J Cardiovasc Pharmacol 2003;42(4):491-6.

21. Wu S.C., Liu C.P., Chiang H.T., Lin S.L. Prospective and randomized study of theantihypertensive effect and tolerability of three antihypertensive agents, losartan, amlodipine, and lisinopril, in hypertensive patients. Heart Vessels 2004;19(1):13-8.

22. McInnes G.T., O'Kane K.P., Istad H. et al. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens 2000;14(4):263-69.

23. Malacco E., Santonastaso M., VarмN.A. et al. Comparison of valsartan 160 mg withlisinopril 20 mg, given as monotherapy or in combination with a diuretic, for thetreatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartanin Comparison with Lisinopril (PREVAIL) study. ClinTher 2004;26(6):855-65.

24. Poldermans D., Glazes R., Kargiannis S. et al. Tolerability and blood pressure-loweringefficacy of the combination of amlodipine plus valsartan compared with lisinoprilplus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007;29(2):279-89.

25. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.

26. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321(7274): 1440-44.

27. EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.

28. Parving H. H. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. J Diabetes Complications 1996; 10 (3): 133-5.

29. Zadionchenko VS, Adasheva TV, Demicheva OY, et al. Arterial hypertension in metabolic syndrome: pathogenesis, Basis of Therapeutics. Consilium medicum, 2004; 6 (9): 663-8. Russian (Задионченко В.С., Адашева Т.В., Демичева О.Ю., и др. Артериальная гипертония при метаболическом синдроме: патогенез, основы терапии. Consilium medicum 2004; 6(9): 663-8).

30. Pozdnjakov YM, Volkov VS, Milyagin VA, Jakushin SS. Monotherapy hypertension grade I-II. Experience of using lisinopril (results of a multicenter study). Bolezni Serdtsa i Sosudov 2006; 1 (4): 47-

31. Russian (Поздняков Ю.М., Волков В.С., Милягин В.А., Якушин С.С.. Монотерапия артериальной гипертонии I-II степени. Опыт применения лизиноприла (результаты многоцентрового исследования). Болезни Сердца и Сосудов 2006; 1(4): 47-50).

32. ChazovaI.E., RatovaL.G. Iruzid and Irumed. Nephroprotection in patients with essential hypertension. Consilium medicum, 2005; 7 (1): 3-7. Russian (ЧазоваИ.Е., РатоваЛ.Г. Ирузид и Ирумед. Нефропротекция в лечении больных артериальной гипертонией. Consilium medicum 2005; 7(1): 3-7).

33. Mancia G., Zanchetti A., Agabiti-Rosei E. et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997; 95 (6); 1464-70.

34. Tepstra WF., May JF., Smit AJ., et al. Long term effect of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001; 19:303-309.

35. Rizzoni D., Muiesan M. L., Porteri E. et al. Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J Hypertension 1997; 15: 197-204.

36. Brilla C.G., Funck R.C., Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.Circulation 2000; 102(12):1388-93.

37. Laviades C, Mayor G, Díez J. Treatment with lisinopril normalizes serum concentrations of procollagen type III amino-terminal peptide in patients with essential hypertension. Am J Hypertens 1994; 7: 52-58.

38. Olbinskaya LI, Morozova TE, Belov AA, Yusupova AO. Pharmacotherapy of patients with arterial hypertension and chronic obstructive pulmonary disease: the possibility of an ACE inhibitor, lisinopril. Lechashchiy Vrach 2008; (1): 62-6. Russian (Ольбинская Л. И., Морозова Т. Е., Белов А. А., ЮсуповаА. О. Фармакотерапия больных артериальной гипертонией в сочетании с хронической обструктивной болезнью легких: возможности ингибитора АПФ лизиноприла. Лечащий Врач 2008; (1): 62-6).

39. Karpov YA, Sorokin EV. Some features of the treatment of hypertension in elderly patients with chronic obstructive pulmonary disease. Russkiy Meditsinskiy Zhurnal 2004; 15: 945-8. Russian (Карпов Ю.А., Сорокин Е.В. Некоторые особенности лечения артериальной гипертонии у пожилых больных с хроническими обструктивными заболеваниями легких. Русский Медицинский Журнал 2004; 15: 945-8).

40. Savenkov MP, Ivanov SA, Okuneva JH et al. Use of lisinopril in patients with hypertension and chronic obstructive pulmonary disease. Rossiyskiy Meditsinskiy Zhurnal 2009; 2: 102-5. Russian (Савенков М. П., Иванов С. А., Окунева И. Н. с соавт. Применение лизиноприла у больных с артериальной гипертонией и хронической обструктивной болезнью легких. Российский Медицинский Журнал 2009; 2: 102-5).

41. Kislyak OA. ACE inhibitor lisinopril in the treatment of elderly patients with isolated systolic and systolicdiastolic hypertension. Lechebnoe Delo 2007; (2): 2-7. Russian (Кисляк О.А. Ингибитор АПФ лизиноприл в лечении пожилых пациентов с изолированной систолической и систоло-диастолической артериальной гипертензией. Лечебное Дело 2007;(2):2-7).

42. Oshchepkova EV. Possibilities of ACE inhibitor lisinopril (Diroton) in the treatment of hypertensive patients with hepatic pathology. Atmosfera. Kardiologiya 2007; 3: 8-11. Russian (Ощепкова Е.В. Возможности ингибитора ангиотензинпревращающего фермента лизиноприла (Диротон) в лечении больных артериальной гипертонией с сопутствующей патологией печени. Атмосфера. Кардиология 2007; 3: 8-11).

43. Drapkina OM, Mayevskaya MV, Korneeva ON, et al. Clinical efficacy and safety Dupree (lisinopril) for liver disease and arterial hypertension. Klinicheskie Perspektivy Gastroenterologii, Gepatologii 2004; 4: 30. Russian (Драпкина О.М., Маевская М.В., Корнеева О.Н., и др. Клиническое исследование эффективности и безопасности даприла (лизиноприла) при патологии печени и сопутствующей артериальной гипертензии. Клинические Перспективы Гастроэнтерологии, Гепатологии 2004; 4: 30).

44. Lazebnik LB, Komissarenko IA, Levchenko SV et al. Effect of angiotensin converting enzyme inhibitors on renal and hepatic function in patients with arterial hypertension in older age groups. Atmosfera. Kardiologiya 2006; 3: 10-8. Russian (Лазебник Л.Б., Комиссаренко И. А., Левченко С. В. и др. Влияние ингибиторов ангиотензинпревращающего фермента на функцию почек и печени у больных артериальной гипертонией старших возрастных групп. Атмосфера. Кардиология 2006; 3: 10-8).

45. Lazebnik LB, Komissarenko IA, Mikheeva OM, et al. Combination therapy of hypertension in combination with liver disease. Place of angiotensin converting enzyme inhibitors. Kardiologiya 2009, 3: 28-33. Russian (Лазебник Л.Б., Комиссаренко И.А., Михеева О.М., и др. Комбинированная терапия артериальной гипертонии в сочетании с патологией печени. Место ингибиторов ангиотензинпревращающего фермента. Кардиология 2009;3: 28-33).

46. Shustval NF. Clinical efficacy and safety of dirotona with hypertension in convalescents after acute viral hepatitis in comparison with other antihypertensive drugs. Ukrainskiy Meditsinskiy Zhurnal 2003; 1: 38-42. Russian (Шустваль Н.Ф. Клиническая эффективность и безопасность применения диротона при гипертонической болезни у реконвалесцентов после перенесенного острого вирусного гепатита в сравнении с другими гипотензивными препаратами. Украинский Медицинский Журнал 2003; 1: 38-42).


For citation:


Dzhaiani N.A. CHOICE OF LISINOPRIL FOR TREATMENT OF HYPERTENSION IN PATIENTS WITH CONCOMITANT DISEASES. Rational Pharmacotherapy in Cardiology. 2014;10(5):565-571. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-5-565-571

Views: 604


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)